Ameloblastoma secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__


[[Ameloblastoma]]
{{Ameloblastoma}}
{{CMG}}{{AE}}{{Simrat}}
{{CMG}}; {{AE}} {{Simrat}}
 
==Overview==
==Overview==
Secondary prevention strategies following ameloblastoma include follow-up examination at regular intervals for at least 10 years.  
Secondary prevention strategies following ameloblastoma include follow-up examination at regular intervals for at least 10 years.
 
==Secondary Prevention==
==Secondary Prevention==
*Regular follow-up examination with the physician is very important in managing ameloblastoma.  
*Regular follow-up examination with the physician is very important in managing [[ameloblastoma]].  
*For ameloblastoma follow up should occur at regular intervals for at least 10 years. Follow up is important, because 50% of all recurrences occur within 5 years postoperatively.
*For [[ameloblastoma]] patients follow up should occur at regular intervals for at least 10 years.
*Recurrence within a bone graft does occur, but is less common. Seeding to the bone graft is suspected as a cause of recurrence. The recurrences in these cases seem to stem from the soft tissues, especially the adjacent periosteum.
*Recurrence has been reported to occur as many as 36 years after treatment. Rates of recurrence may be as high as 15% to 25% after radical treatment and 75% to 90% after conservative treatment. Therefore, wide resection of the jaw in accordance with the treatment of malignant tumors is usually recommended for ameloblastomas. Recent advancements in understanding the biological behaviors of ameloblastoma have led to more rational surgical approaches. To reduce the likelihood of recurrence within grafted bone, meticulous surgery with attention to the adjacent soft tissues is required.
==References==
==References==
{{reflist|2}}
{{reflist|2}}



Latest revision as of 14:44, 31 May 2019


Ameloblastoma Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ameloblastoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ameloblastoma secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ameloblastoma secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ameloblastoma secondary prevention

CDC on Ameloblastoma secondary prevention

Ameloblastoma secondary prevention in the news

Blogs on Ameloblastoma secondary prevention

Directions to Hospitals Treating Ameloblastoma

Risk calculators and risk factors for Ameloblastoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]

Overview

Secondary prevention strategies following ameloblastoma include follow-up examination at regular intervals for at least 10 years.

Secondary Prevention

  • Regular follow-up examination with the physician is very important in managing ameloblastoma.
  • For ameloblastoma patients follow up should occur at regular intervals for at least 10 years.

References

Template:WH Template:WS